Science Explorer Back to mapMap

Most cited papers from Stealth BioTherapeutics (United States)

Stealth BioTherapeutics (United States)

What are the most cited papers from Stealth BioTherapeutics (United States)?

The most cited paper from Stealth BioTherapeutics (United States) is "Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness*" (Scott K. Powers, Matthew B. Hudson, W. Bradley Nelson et al., 2011), with 253 citations. Next come "MAP3K11/GDF15 axis is a critical driver of cancer cachexia" (188) and "The NeurostationTM—A highly accurate, minimally invasive solution to frameless stereotactic neurosurgery" (182).

Showing 49 of 49 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness* Scott K. Powers, Matthew B. Hudson, W. Bradley Nelson et al. · Critical Care Medicine Open access Apr 2011 253
2 MAP3K11/GDF15 axis is a critical driver of cancer cachexia Lorena R. Lerner, Julie Tao, Qing H. Liu et al. · Journal of Cachexia Sarcopenia and Muscle Open access 29 Oct 2015 188
3 The NeurostationTM—A highly accurate, minimally invasive solution to frameless stereotactic neurosurgery Kurt R. Smith, Kevin J. Frank, Richard D. Bucholz · Computerized Medical Imaging and Graphics Jul 1994 182
4 Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy Amel Karaa, Richard Haas, Amy C. Goldstein et al. · Neurology Open access 2 Mar 2018 155
5 A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism William Reid Thompson, Brittany Hornby, Ryan Manuel et al. · Genetics in Medicine Open access 19 Oct 2020 136
6 Frameless stereotactic ultrasonography: Method and applications Jason W. Trobaugh, William D. Richard, Kurt R. Smith et al. · Computerized Medical Imaging and Graphics Jul 1994 131
7 Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial Javed Butler, Muhammad Shahzeb Khan, Stefan D. Anker et al. · Journal of Cardiac Failure Open access 14 Feb 2020 111
8 Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy Amel Karaa et al. · Neurology Open access 2 Jun 2023 81
9 Design and engineering of deimmunized biotherapeutics Karl E. Griswold, Chris Bailey‐Kellogg · Current Opinion in Structural Biology ReviewOpen access 18 Jun 2016 54
10 The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview Marielle Goyette Contesse, James E. Valentine, Tracy Wall et al. · Advances in Therapy Open access 16 Mar 2019 43
11 Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER William Reid Thompson, Ryan Manuel, Anthony Abbruscato et al. · Genetics in Medicine Open access 8 Apr 2024 41
12 Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity Regina S. Salvat, Deeptak Verma, Andrew Scott Parker et al. · Proceedings of the National Academy of Sciences Open access 12 Jun 2017 40
13 ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation Justis P. Ehlers et al. · Ophthalmology Science Open access 9 Oct 2024 35
14 Exploring the Acceleration Limits of Deep Learning Variational Network–based Two-dimensional Brain MRI Alireza Radmanesh, Matthew J. Muckley, Tullie Murrell et al. · Radiology Artificial Intelligence Open access Nov 2022 32
15 SBT-272 improves TDP-43 pathology in ALS upper motor neurons by modulating mitochondrial integrity, motility, and function Mukesh Gautam, Barış Genç, Benjamin Helmold et al. · Neurobiology of Disease Open access 27 Jan 2023 29
16 Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing Hongliang Zhao, Seth A. Brooks, Susan K. Eszterhas et al. · Science Advances Open access 2 Sep 2020 29
17 Intraoperative localization using a three-dimensional optical digitizer Richard D. Bucholz, Kurt R. Smith, Jaimie M. Henderson et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE Conference paper 17 Sep 1993 27
18 A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008–2015 Bruce Cohen, Cristy Balcells, Brian Hotchkiss et al. · Orphanet Journal of Rare Diseases Open access 22 Nov 2018 25
19 Patient Voice in Rare Disease Drug Development and Endpoints Linda S. Deal, Jonathan C. Goldsmith, Susan A. Martin et al. · Therapeutic Innovation & Regulatory Science 4 Nov 2016 25
20 Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome Brittany Hornby, William Reid Thompson, Mohammed Almuqbil et al. · Orphanet Journal of Rare Diseases Open access 2 Sep 2022 24
21 The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction Marcus Hortmann, Samuel D. Robinson, M. Mohr et al. · European Heart Journal Acute Cardiovascular Care Open access 23 May 2017 24
22 Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial Amel Karaa et al. · Orphanet Journal of Rare Diseases Open access 21 Nov 2024 14
23 Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics Yongliang Fang, Jack R. Kirsch, Liang Li et al. · Antimicrobial Agents and Chemotherapy Open access 14 Dec 2020 13
24 Safety, pharmacokinetics and pharmacodynamics of SBT‐020 in patients with early stage Huntington's disease, a 2‐part study Marcus P.J. van Diemen, Ellen P. Hart, Anthony Abbruscato et al. · British Journal of Clinical Pharmacology Open access 16 Nov 2020 13
25 The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment and activation during apoptosis Joshua A. Grosser, Rachel L. Fehrman, Dennis Keefe et al. · BMC Research Notes Open access 22 May 2021 10
26 Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial) Yazan Daaboul, Serge Korjian, W. Douglas Weaver et al. · The American Journal of Cardiology 18 Jun 2016 10
27 Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease Chad J. Gwaltney, Jonathan Stokes, Anthony Aiudi et al. · Journal of Patient-Reported Outcomes Open access 23 Dec 2022 9
28 Development and content validity of the Barth Syndrome Symptom Assessment (BTHS-SA) for adolescents and adults Chad J. Gwaltney, Jonathan Stokes, Anthony Aiudi et al. · Orphanet Journal of Rare Diseases Open access 9 Jun 2021 8
29 Patient Guidance and Remote Care With AI and AR Prashant Singh, Gaurav Prasad, Harmohinder S. Athwal et al. · Advances in healthcare information systems and administration book series Book chapter 16 Aug 2024 4
30 Cellular Context Dictates the Suppression or Augmentation of Triple-Negative Mammary Tumor Metastasis by NLRX1 Margaret A. Nagai-Singer, Mackenzie K. Woolls, Katerina Leedy et al. · The Journal of Immunology Open access Nov 2023 4
31 Metabolomic biomarkers from patients with Barth syndrome treated with elamipretide: insights from the TAZPOWER study Peter J. Oates, David Alexander Brown, Hilary J. Vernon et al. · medRxiv PreprintOpen access 23 Nov 2020 4
32 Development of a Patient-Reported Outcome Questionnaire to Evaluate Primary Mitochondrial Myopathy Symptoms: The Primary Mitochondrial Myopathy Symptom Assessment Chad J. Gwaltney, Jonathan Stokes, Anthony Aiudi et al. · Journal of Clinical Neuromuscular Disease 17 Nov 2020 4
33 Frameless image-guided surgery utilizing an optical digitizer Richard D. Bucholz, Kurt R. Smith, Lee L. McDurmont et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE Conference paper 26 May 1994 4
34 Extracellular Thimet Oligopeptidase is Released with Extracellular Vesicles from Human Prostate Cancer Cells Yu Liu, Lisa A. Bruce, Adele J. Wolfson · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 10 May 2020 3
35 ЕФЕКТИВНІСТЬ ВИКОРИСТАННЯ КВАНТОВИХ КОМП’ЮТЕРІВ У РОЗВ’ЯЗАННІ СКЛАДНИХ ЗАВДАНЬ Oleg Bondarchuk, Serhii Zybin, Svitlana Vasylyuk-Zaitseva · INFORMATION TECHNOLOGY AND SOCIETY Open access 30 Dec 2024 1
36 Genetic subgroup learnings from MMPOWER-3 trial: Elamipretide improved six-minute walk test in individuals with mtDNA replisome disorders Amel Karaa, Michelangelo Mancuso, Bruce M. Cohen et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics Open access 20 Aug 2022 1
37 The mitochondria-targeting peptide Elamipretide preserves mitochondrial function and protects the heart against ischemia-reperfusion damage Janis Kuka, Marina Makrecka‐Kuka, Edijs Vavers et al. · Proceedings for Annual Meeting of The Japanese Pharmacological Society Open access 2018 1
38 Breaking and fixing content-based filtering Mayank Dhiman, Markus Jakobsson, Ting-Fang Yen Conference paper Apr 2017 1
39 Bulk RNAseq of cardiac myosin-specific CD4 and CD8 T cells reveals distinct transcriptomic profiles between myocarditis-resistant and susceptible mice 2256473 Shraddha Singh, Meghna Sur, Kiruthiga Mone et al. · The Journal of Immunology 28 Jul 2026 0
40 Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices Barbara A. Hendrickson, Cynthia McShea, Tarek A. Hammad et al. · Pharmaceutical Medicine Open access 16 Dec 2025 0
41 Unpaired Electrons-Empowered Bridge-Site Lattice Oxygen for Efficient CO 2 -to-CH 4 Conversion via a CO 2 /H 2 Fuel Cell Yan Liu, Yan Liu, Ji‐Xiang Hu et al. · Nano Letters 13 Dec 2025 0
42 Bulk RNAseq Analysis of Cardiac Myosin-Specific CD4+ and CD8+ T Cells Reveals Distinct Transcriptomic Profiles Between Myocarditis-Resistant and Susceptible Mice Shraddha Singh, Meghna Sur, Kiruthiga Mone et al. · Biomedicines Open access 6 Nov 2025 0
43 Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study Chad J. Gwaltney, Alan L. Shields, Emily Love et al. · Orphanet Journal of Rare Diseases Open access 25 Apr 2025 0
44 Cellular protection and preservation of bioenergetics by the novel compound SBT-589 in a fibroblast model of Leigh syndrome Laura E. Kropp, Alyssa Handler, Hatim A. Zariwala et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics Open access 26 Aug 2024 0
45 Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover Study Sandrin C. Bergheanu, Benjamin D. McNeil, Alana Sullivan et al. PreprintOpen access 12 Jul 2023 0
46 Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover Study Alana Sullivan, Sandrin C. Bergheanu, Laura E. Kropp et al. PreprintOpen access 6 Apr 2023 0
47 SBT-272 improves TDP-43 pathology in the ALS motor cortex by modulating mitochondrial integrity, motility, and function Mukesh Gautam, Barış Genç, Benjamin Helmold et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access 7 Oct 2022 0
48 Preservation of bioenergetics and inhibition of ferroptosis with the novel compound SBT-588 in Friedreich’s ataxia cell models Laura E. Kropp, Hatim A. Zariwala, Yunmi Park et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics Open access 20 Aug 2022 0
49 Elamipretide Prevents the Natural History Progression of Cardiomyopathy-Related Disease Symptomatology in Patients with Barth Syndrome: A Tazpower Analysis William Reid Thompson, Ryan Manuel, John J. Jones et al. · Journal of Cardiac Failure 30 Sep 2020 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.